We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




More Accurate Use of Antibiotics Could Save the NHS GBP 500 Million Annually

By LabMedica International staff writers
Posted on 19 Aug 2014
The UK National Health Service (NHS; UK) could save an estimated GBP 500 million each year while reducing the threat of antibiotic resistance by managing the use of antibiotics with more accurate diagnostics. More...


Against a backdrop of growing global concern, the UK has responded with a major initiative to tackle antimicrobial resistance, with the establishment of a cabinet aimed at combining the minds and efforts of leading research bodies to achieve a collective response. As new research from Public Health England and University College London revealed that the proportion of UK patients given antibiotics for coughs and colds has risen by a staggering 40% since 2000, the debate around the issue assumes additional urgency.

“This study further validates our concerns and reinforces the pressing need for real action," said Dr. Peter FitzGerald, Managing Director at Randox, "There are solutions – new technology to improve diagnostics is available. We are calling on the newly established ‘war cabinet on antimicrobial resistance’ to engage this technology as part of their weaponry and start tackling the issue at the frontline.” As the search for answers continues, Dr. FitzGerald recommends that the cabinet and the medical community make a rapid appraisal of existing innovative technologies with the ability to help.

More accurate diagnosis will improve patient care, reduce unnecessary prescribing, and reduce cost. An estimated 1 million people each year across the UK spend at least 1 week in hospital due to respiratory infections. Using basic calculations, scientists at Randox Laboratories Ltd. (Crumlin, Northern Ireland) estimated that through reducing the average length of hospital stay from 7 to 5 days for patients admitted with respiratory infections, the NHS could save GBP 500 million each year.

Early, first-time diagnosis is critical and scientists at Randox have revealed their latest weapon in the fight against antibiotic resistance: a new test for the identification of respiratory infections—the Randox Respiratory Array. The test screens patient saliva, mucus, or sputum and can accurately identify up to 22 infections, both viral and bacterial, simultaneously, with results to the physician on the same day. The test will contribute to much needed progress, enabling doctors to prescribe the correct antibiotic (not just "an" antibiotic), or another form of effective medication.

"By utilizing our existing resources and employing pioneering technology to inform diagnosis, we can facilitate a much needed behavioral change in prescribing habits," said Dr. FitzGerald. With advanced diagnostic tests such as the Randox Respiratory Array, many infections can be diagnosed accurately within the same day, empowering doctors to prescribe appropriate treatment at first presentation, rather than a "one size fits all" tendency in the current overprescribing of antibiotics.

Related Links:

Randox
National Health Service



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.